Atom Bioscience initiated patient enrolment in the US for a P-IIb/III study of ABP-671 in oral formulation to treat Chronic Gout
P-IIb/III study (n=580) evaluates ABP-671 in two parts; Part 1 for safety and efficacy at different doses and regimens vs PBO or allopurinol (SOC) in the US; Part 2 for comparing dose regimens selected from Part 1 with PBO in patients who were not enrolled in Part 1; identified 36 sites in 17 states
ABP-671, an orally administered URAT1 inhibitor; preclinical data showed significant efficacy and good safety, whereas existing drugs showed poor efficacy and SAEs (incl. kidney failure, sudden cardiac death, or severe liver toxicity)
Ref: Atom Bioscience | Image: Atom Bioscience
Related News:- Alvotech and Teva Pharmaceuticals Collaborate to Expand Access for Adalimumab-ryvk (Interchangeable Biosimilar, Humaira) in US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
